In the three-patient case series by Makis et al. (2025), the breast cancer patient’s outcome (Case 1) shares several key similarities with the prostate cancer (Case 2) and melanoma (Case 3) cases—notably sustained remissions on low-dose fenbendazole without cytotoxic chemotherapy—while differing in response depth, concurrent standard therapies, tracking biomarkers, and follow-up duration.
